Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations

Berghmans Thierry, Meert Anne-Pascale, Quoix Elisabeth

Source: Eur Respir J 2015; 46: 19-21

Journal Issue: July

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Berghmans Thierry, Meert Anne-Pascale, Quoix Elisabeth. Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations. Eur Respir J 2015; 46: 19-21

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Second-line combination therapies in nonsmall cell lung cancer without known driver mutations Source: Eur Respir Rev 2015; 24: 582-593 Year: 2015
Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014
Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017
The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013
Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009
Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015
Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011
Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009
Targeted therapy for nonsmall cells Source: Annual Congress 2007 - NSCC - Targeted therapy for nonsmall cells Year: 2007
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006
Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019